Search Results - "Bulbake, Upendra"

  • Showing 1 - 11 results of 11
Refine Results
  1. 1

    Liposomal Formulations in Clinical Use: An Updated Review by Bulbake, Upendra, Doppalapudi, Sindhu, Kommineni, Nagavendra, Khan, Wahid

    Published in Pharmaceutics (27-03-2017)
    “…Liposomes are the first nano drug delivery systems that have been successfully translated into real-time clinical applications. These closed bilayer…”
    Get full text
    Journal Article Book Review
  2. 2

    Chitosan sponges as a sustained release carrier system for the prophylaxis of orthopedic implant-associated infections by Pawar, Vaishali, Bulbake, Upendra, Khan, Wahid, Srivastava, Rohit

    “…The present investigation aims to study the chitosan sponge as a carrier matrix for the sustained antibiotic release system for the prophylaxis of orthopedic…”
    Get full text
    Journal Article
  3. 3

    Therapeutic Macromolecular Iron Chelators by Bulbake, Upendra, Singh, Alka, Domb, Abraham J, Khan, Wahid

    Published in Current medicinal chemistry (01-01-2019)
    “…Iron is a key element for every single living process. On a fundamental level, targeting iron is a valuable approach for the treatment of disorders caused by…”
    Get more information
    Journal Article
  4. 4

    Preparation, characterization, and in vivo evaluation of cyclosporine cationic liposomes for the treatment of psoriasis by Walunj, Manoj, Doppalapudi, Sindhu, Bulbake, Upendra, Khan, Wahid

    Published in Journal of liposome research (02-01-2020)
    “…Cyclosporine (CYC), a calcineurin inhibitor acts specifically on T-cells and is one of the most effective treatment options for psoriasis. Systemic…”
    Get full text
    Journal Article
  5. 5

    Cabazitaxel and thymoquinone co-loaded lipospheres as a synergistic combination for breast cancer by Kommineni, Nagavendra, Saka, Raju, Bulbake, Upendra, Khan, Wahid

    Published in Chemistry and physics of lipids (01-11-2019)
    “…[Display omitted] •Cabazitaxel(CBZ) as microtubule inhibitor and thymoquinone (TMQ) as HDAC inhibitor affects the important genes like p53, STAT3, Bax, BCL-2,…”
    Get full text
    Journal Article
  6. 6

    Liposphere mediated topical delivery of Thymoquinone in the treatment of psoriasis by Jain, Anjali, Venkatesh, P, Bulbake, Upendra, Doppalapudi, Sindhu, Rafeeqi, Towseef Amin, Godugu, Chandraiah, Khan, Wahid

    Published in Nanomedicine (01-10-2017)
    “…Abstract Thymoquinone (TMQ) is reported with good anti-psoriatic activity however, the hydrophobicity, poor aqueous solubility, light and pH sensitive nature…”
    Get full text
    Journal Article
  7. 7

    Comparison of cationic liposome and PAMAM dendrimer for delivery of anti-Plk1 siRNA in breast cancer treatment by Bulbake, Upendra, Kommineni, Nagavendra, Ionov, Maksim, Bryszewska, Maria, Khan, Wahid

    Published in Pharmaceutical development and technology (02-01-2020)
    “…Delivery of negatively charged, high molecular weight and unstable siRNA is difficult. The present study describes the development and comparison of cationic…”
    Get full text
    Journal Article
  8. 8

    Cationic liposomes for co-delivery of paclitaxel and anti-Plk1 siRNA to achieve enhanced efficacy in breast cancer by Bulbake, Upendra, Kommineni, Nagavendra, Bryszewska, Maria, Ionov, Maksim, Khan, Wahid

    “…Combined effects of anticancer drug and siRNA have shown superior advantages for cancer chemotherapy. Herein, we analyzed the feasibility whether anticancer…”
    Get full text
    Journal Article
  9. 9

    Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products by Thummar, Mohit, Kuswah, Bhoopendra S., Samanthula, Gananadhamu, Bulbake, Upendra, Gour, Jitendra, Khan, Wahid

    “…[Display omitted] •Olaperib is used to treat prostate, ovarian and breast cancer in the patients with hereditary BRCA1 and BRCA2 mutations.•This is the first…”
    Get full text
    Journal Article
  10. 10

    Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib by Pathade, Akshay D., Kommineni, Nagavendra, Bulbake, Upendra, Thummar, Mohit M., Samanthula, Gananadhamu, Khan, Wahid

    Published in AAPS PharmSciTech (06-08-2019)
    “…Olaparib (OLA) is a poly ADP ribose polymerase (PARP) inhibitor approved for germline BRCA-mutated (gBRCAm) advanced ovarian cancer and breast cancer. Low oral…”
    Get full text
    Journal Article
  11. 11

    Curcumin loaded biomimetic composite graft for faster regeneration of skin in diabetic wounds by Bulbake, Upendra, Jain, Sonam, Kumar, Neeraj, Mittal, Anupama

    “…Diabetic wounds do not heal in an organized and timely manner due to poor blood glucose control and weakened immune system. In the present study, wound healing…”
    Get full text
    Journal Article